Retina

The goal is to evaluate neonates with retinopathy of prematurity (ROP) who met only 1 screening criterion with the goal of easing the burden of ROP screening.

The company’s AI CLAIR technology platform has received FDA breakthrough device status, and if cleared by the FDA will deliver real-time cardiovascular disease risk assessments through routine eye exams.

The clinical trial will evaluate the safety and efficacy of CLS-AX (axitinib injectable suspension), a tyrosine kinase inhibitor. According to the company, topline data is expected during the third quarter of 2024.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

Researchers have delved into the possibility of cell-based therapy in ophthalmology. By targeting vitreoretinal diseases, they are tackling a range of vision-threatening disorders which often result in severe irreversible vision loss.

Technology allows partitioning of sequencing reads into 2 parental genome data sets.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss 2 cases of CRAO immediate post-op uncomplicated cataract surgery under topical anesthesia treated with intra-ophthalmic artery fibrinolysis within 6 hours after symptom onset.

Developing technology may offer marked improvements in surgical precision

Mutations in the EMC1 gene appear to be associated with FEVR, a severe ocular condition.

Polish researchers found positive bacterial cultures in premature infants correlated with severe retinopathy of prematurity (ROP), suggesting a potential prognostic marker for early ROP development.

Prevent Blindness emphasizes the importance of proper eye protection, as exposure to the sun during an eclipse can cause "eclipse blindness" or retinal burns, which can be temporary or permanent.

According to Roche, faricimab (Vabysmo)showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies.

G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

The company announced preliminary US net revenues of about $74 million for the injection, approved by the FDA earlier this year.

This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.

The collaboration will drive an effort to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.

In this EyePod® episode, David Hutton sits down with Shankar Musunuri, CEO of Ocugen to discuss updated data for OCU400.

The specialty pharmaceutical research company’s new retinal vascular dysfunction model can have an impact on the research and development of new drugs for retinal vascular diseases.

According to a news release, the J-code for SYFOVRE will become effective on October 1, 2023.

To educate patients on the disease, the company has enlisted the help of actor Eric Stonestreet and his mother, Jamey.

Kiora CEO Brian Strem, PhD, offers an update on the development of KIO-301, a molecule that selectively targets retinal ganglion cells, giving them the ability to sense light.

The research will focus on the compound's impact on biomolecular condensates, which are implicated as a key driver of pathology in neurodegeneration and diseases impacting high metabolic organs. Because the retina is one of the highest energy consuming systems in the human body, deficits in energy supply can be catastrophic.

Researchers from the University of Barcelona are looking to unlock the function of genes in order to design therapies to treat patients diagnosed with retinitis pigmentosa.

Leaders must confront issues perpetuating unequal access, unfair practices.

The company has released a video presentation that highlights combining genetic markers with high-resolution retinal imaging to assist in the detection and treatment of blindness and multiple systemic diseases.